source
- Novo Nordisk halts two late-stage ziltivekimab heart trials after futility findingNovo Nordisk announced it has stopped work early on two additional late-stage clinical studies of its IL-6 inhibitor ziltivekimab, which was being evaluated for heart disease. The decision followe…
- Claret Capital Partners raises €575 million Fund IV to boost European biotech lendingClaret Capital Partners, a European investment firm, announced that its fourth fund has closed at €575 million. The firm said a significant share of the capital will be deployed as loans to life-s…